A recent article published by the Infectious Disease Special Edition highlights the safety and efficacy demonstrated by Sanaria's non-replicating whole parasite PfSPZ malaria vaccine candidate.
The new study involved 80 participants in a randomized controlled clinical trial comparing three doses of the PfSPZ vaccine against a placebo.
Vaccine efficacy was shown to be 48% at six months (P=0.061) and 46% at 18 months (P=0.018).
Read More
